Biocon Limited reports a 10% rise in operating revenue, driven by a 17% increase in biopharma sales, amid strategic shifts towards biosimilars and a stronger US market outlook for FY27.
Biocon Limited said its consolidated operating revenue rose 10% year on year to Rs 4,336 crore in the fiscal first quarter ended June 30, 2026, as strength in its biopharma division offset weakness in services. The Bengaluru-based drugmaker also reported consolidated EBITDA of Rs 902 crore, with a margin of 21%, while net profit before exceptional items came in at Rs 145 crore.
The company said biopharma revenue climbed 17% in the quarter, helped by momentum from recent biosimilar and generic launches across key markets. Biosimilars revenue increased 16% to Rs 2,855 crore and generics revenue rose 21% to Rs 760 crore, while services revenue fell 16% to Rs 736 crore, reflecting continuing difficulties in that business.
Chief executive Shreehas Tambe said Biocon had entered FY27 aiming to turn earlier investments into longer-term growth, with a particular focus on North America, its largest market. He also pointed to a more supportive policy backdrop for biosimilars, expanded manufacturing capacity in the United States and new capabilities in research services as reasons for confidence in the year ahead.
Biocon has been trying to sharpen its focus on biosimilars and generics to improve capacity use, profitability and returns on capital, according to LiveMint’s report on the company’s strategy. The same report said Tambe wants to bring the businesses together as a single biopharmaceutical platform with broader scale and reach.
The company also said it has continued to strengthen its balance sheet, with interest costs falling 23% to Rs 213 crore from Rs 277 crore a year earlier. Earlier company disclosures said Biocon raised about $1 billion through two qualified institutional placements over eight months and settled structured debt, moves it said were intended to reduce leverage and support future earnings. Analysts cited by Arthneeti expect growth to pick up later in FY27 and into FY28 as more biosimilar launches and additional insulin capacity come on stream.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
